<ul>
<li>可能还有时间投资这三家热门生物科技公司</li>
</ul>
<p>Sana Biotechnology, Inc. (NASDAQ:SANA - 免费报告) - HC Wainwright 的股票研究分析师在 4 月 14 日星期二发布的研究报告中上调了对 Sana Biotechnology 2026 年第二季度每股收益 (EPS) 的预期。HC Wainwright 分析师 E. Bodnar 现在预测该公司本季度每股收益为（$0.12），高于之前的预测（$0.13）。HC Wainwright 对该股票给予 &#34;买入&#34; 评级，目标价为 $7.00。市场普遍预期 Sana Biotechnology 当前全年的每股收益为（$1.16）。HC Wainwright 还对 Sana Biotechnology 2026 财年的每股收益预期为（$0.52），2027 财年为（$0.58），2028 财年为（$0.63），2029 财年为（$0.65）。</p>
<p>获取 <strong>Sana Biotechnology</strong> 警报：</p>
<p>Sana Biotechnology (NASDAQ:SANA - 获取免费报告) 最近在 3 月 3 日星期二发布了其财报。该公司报告本季度每股收益为（$0.16），低于市场普遍预期的（$0.13），差额为（$0.03）。</p>
<p>其他分析师也对该公司发布了报告。Zacks Research 在 3 月 3 日星期二的报告中将 Sana Biotechnology 的评级从 &#34;强烈买入&#34; 下调至 &#34;持有&#34;。Wedbush 在星期二的报告中将 Sana Biotechnology 的目标价从 $6.00 上调至 $7.00，并给予该公司 &#34;跑赢大盘&#34; 的评级。Weiss Ratings 在星期二的报告中重申了对 Sana Biotechnology 股票的 &#34;卖出（d-）&#34; 评级。美国银行在 1 月 6 日星期二的报告中将 Sana Biotechnology 的目标价从 $6.00 上调至 $7.00，并给予该公司 &#34;买入&#34; 评级。最后，华尔街 Zen 在 2 月 7 日星期六的报告中将 Sana Biotechnology 的评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。六位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Sana Biotechnology 当前的平均评级为 &#34;适度买入&#34;，共识目标价为 $8.20。</p>
<p><strong>查看我们最新的 Sana Biotechnology 股票报告</strong></p>
<h2>Sana Biotechnology 股价下跌 1.1%</h2>
<p>SANA 股票在星期四开盘价为 $3.44。该公司的 50 日移动平均价格为 $3.48，200 日移动平均价格为 $4.13。该公司的市值为 $9.1803 亿，市盈率为 -3.55，贝塔值为 2.06。Sana Biotechnology 的一年低点为 $1.53，一年高点为 $6.55。</p>
<h2>对 Sana Biotechnology 的对冲基金看法</h2>
<p>机构投资者最近买入和卖出了该公司的股票。洛克菲勒资本管理公司在第四季度将其在 Sana Biotechnology 的持股增加了 74.3%。洛克菲勒资本管理公司现在拥有 9,588 股该公司的股票，价值 $39,000，此前在上个季度又购买了 4,088 股。TD Waterhouse Canada Inc. 在第三季度获得了 Sana Biotechnology 的新头寸，价值约 $37,000。LRI Investments LLC 在第四季度获得了 Sana Biotechnology 的新头寸，价值约 $41,000。Jacobi Capital Management LLC 在第四季度获得了 Sana Biotechnology 的新头寸，价值约 $41,000。最后，Mercer Global Advisors Inc. ADV 在第三季度获得了 Sana Biotechnology 的新头寸，价值约 $36,000。机构投资者和对冲基金持有该公司 88.23% 的股票。</p>
<h2>Sana Biotechnology 公司简介</h2>
<p>（获取免费报告）</p>
<p>Sana Biotechnology 是一家临床阶段的生物制药公司，专注于开发工程细胞作为药物，旨在治疗广泛的疾病。该公司应用先进的基因编辑和基因传递技术，创造用于肿瘤学、遗传疾病和其他严重疾病的下一代细胞治疗产品。通过利用体外和体内的方法，Sana 旨在修复或替换受损细胞，恢复健康的组织功能。</p>
<p>该公司的核心平台整合了专有的基因写入能力以及已建立的基因编辑工具，如 CRISPR–Cas9。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，而不是 Sana Biotechnology</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ"/></p>
<p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Sana Biotechnology 吗？</h2>
<p>在你考虑投资 Sana Biotechnology 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Sana Biotechnology 并不在名单上。</p>
<p>虽然 Sana Biotechnology 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>查看这五只股票</p>

SANA

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

IBBQ

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

<p>HC Wainwright 将 Sana Biotechnology (NASDAQ:SANA) 2026 年第二季度每股收益预期从（$0.13）上调至（$0.12），维持 “买入” 评级，目标价为 $7.00。全年每股收益的共识预期为（$1.16）。其他分析师的评级各异，其中六位给予买入评级，一位给予卖出评级。Sana 的股票开盘价为 $3.44，市值为 $9.1803 亿。该公司专注于针对各种疾病的工程细胞疗法，利用先进的基因编辑技术</p>

<ul>
<li>There May Still Be Time to Get in on These 3 Trending Biotechs</li>
</ul>
<div class="lb-trans"><ul>
<li>可能还有时间投资这三家热门生物科技公司</li>
</ul>
</div><p>Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) - Equities research analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for Sana Biotechnology in a research note issued on Tuesday, April 14th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.12) per share for the quarter, up from their previous estimate of ($0.13). HC Wainwright has a &#34;Buy&#34; rating and a $7.00 price objective on the stock. The consensus estimate for Sana Biotechnology's current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Sana Biotechnology's FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.58) EPS, FY2028 earnings at ($0.63) EPS and FY2029 earnings at ($0.65) EPS.</p>
<div class="lb-trans"><p>Sana Biotechnology, Inc. (NASDAQ:SANA - 免费报告) - HC Wainwright 的股票研究分析师在 4 月 14 日星期二发布的研究报告中上调了对 Sana Biotechnology 2026 年第二季度每股收益 (EPS) 的预期。HC Wainwright 分析师 E. Bodnar 现在预测该公司本季度每股收益为（$0.12），高于之前的预测（$0.13）。HC Wainwright 对该股票给予 &#34;买入&#34; 评级，目标价为 $7.00。市场普遍预期 Sana Biotechnology 当前全年的每股收益为（$1.16）。HC Wainwright 还对 Sana Biotechnology 2026 财年的每股收益预期为（$0.52），2027 财年为（$0.58），2028 财年为（$0.63），2029 财年为（$0.65）。</p>
</div><p>Get <strong>Sana Biotechnology</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sana Biotechnology</strong> 警报：</p>
</div><p>Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.03).</p>
<div class="lb-trans"><p>Sana Biotechnology (NASDAQ:SANA - 获取免费报告) 最近在 3 月 3 日星期二发布了其财报。该公司报告本季度每股收益为（$0.16），低于市场普遍预期的（$0.13），差额为（$0.03）。</p>
</div><p>Other analysts have also issued reports about the company. Zacks Research lowered Sana Biotechnology from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, March 3rd. Wedbush boosted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Sana Biotechnology in a report on Tuesday. Bank of America boosted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, January 6th. Finally, Wall Street Zen lowered Sana Biotechnology from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, February 7th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Sana Biotechnology currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $8.20.</p>
<div class="lb-trans"><p>其他分析师也对该公司发布了报告。Zacks Research 在 3 月 3 日星期二的报告中将 Sana Biotechnology 的评级从 &#34;强烈买入&#34; 下调至 &#34;持有&#34;。Wedbush 在星期二的报告中将 Sana Biotechnology 的目标价从 $6.00 上调至 $7.00，并给予该公司 &#34;跑赢大盘&#34; 的评级。Weiss Ratings 在星期二的报告中重申了对 Sana Biotechnology 股票的 &#34;卖出（d-）&#34; 评级。美国银行在 1 月 6 日星期二的报告中将 Sana Biotechnology 的目标价从 $6.00 上调至 $7.00，并给予该公司 &#34;买入&#34; 评级。最后，华尔街 Zen 在 2 月 7 日星期六的报告中将 Sana Biotechnology 的评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。六位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Sana Biotechnology 当前的平均评级为 &#34;适度买入&#34;，共识目标价为 $8.20。</p>
</div><p><strong>Check Out Our Latest Stock Report on Sana Biotechnology</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Sana Biotechnology 股票报告</strong></p>
</div><h2>Sana Biotechnology Trading Down 1.1%</h2>
<div class="lb-trans"><h2>Sana Biotechnology 股价下跌 1.1%</h2>
</div><p>SANA stock opened at $3.44 on Thursday. The business's 50-day moving average price is $3.48 and its two-hundred day moving average price is $4.13. The firm has a market cap of $918.03 million, a PE ratio of -3.55 and a beta of 2.06. Sana Biotechnology has a 1-year low of $1.53 and a 1-year high of $6.55.</p>
<div class="lb-trans"><p>SANA 股票在星期四开盘价为 $3.44。该公司的 50 日移动平均价格为 $3.48，200 日移动平均价格为 $4.13。该公司的市值为 $9.1803 亿，市盈率为 -3.55，贝塔值为 2.06。Sana Biotechnology 的一年低点为 $1.53，一年高点为 $6.55。</p>
</div><h2>Hedge Funds Weigh In On Sana Biotechnology</h2>
<div class="lb-trans"><h2>对 Sana Biotechnology 的对冲基金看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. increased its position in Sana Biotechnology by 74.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company's stock worth $39,000 after buying an additional 4,088 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new position in Sana Biotechnology during the third quarter worth approximately $37,000. LRI Investments LLC acquired a new position in Sana Biotechnology during the fourth quarter worth approximately $41,000. Jacobi Capital Management LLC acquired a new position in Sana Biotechnology during the fourth quarter worth approximately $41,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Sana Biotechnology during the third quarter worth approximately $36,000. Institutional investors and hedge funds own 88.23% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近买入和卖出了该公司的股票。洛克菲勒资本管理公司在第四季度将其在 Sana Biotechnology 的持股增加了 74.3%。洛克菲勒资本管理公司现在拥有 9,588 股该公司的股票，价值 $39,000，此前在上个季度又购买了 4,088 股。TD Waterhouse Canada Inc. 在第三季度获得了 Sana Biotechnology 的新头寸，价值约 $37,000。LRI Investments LLC 在第四季度获得了 Sana Biotechnology 的新头寸，价值约 $41,000。Jacobi Capital Management LLC 在第四季度获得了 Sana Biotechnology 的新头寸，价值约 $41,000。最后，Mercer Global Advisors Inc. ADV 在第三季度获得了 Sana Biotechnology 的新头寸，价值约 $36,000。机构投资者和对冲基金持有该公司 88.23% 的股票。</p>
</div><h2>Sana Biotechnology Company Profile</h2>
<div class="lb-trans"><h2>Sana Biotechnology 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.</p>
<div class="lb-trans"><p>Sana Biotechnology 是一家临床阶段的生物制药公司，专注于开发工程细胞作为药物，旨在治疗广泛的疾病。该公司应用先进的基因编辑和基因传递技术，创造用于肿瘤学、遗传疾病和其他严重疾病的下一代细胞治疗产品。通过利用体外和体内的方法，Sana 旨在修复或替换受损细胞，恢复健康的组织功能。</p>
</div><p>The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.</p>
<div class="lb-trans"><p>该公司的核心平台整合了专有的基因写入能力以及已建立的基因编辑工具，如 CRISPR–Cas9。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Sana Biotechnology</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Sana Biotechnology</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=SANA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sana Biotechnology Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Sana Biotechnology 吗？</h2>
</div><p>Before you consider Sana Biotechnology, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Sana Biotechnology 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Sana Biotechnology 并不在名单上。</p>
</div><p>While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sana Biotechnology 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

HC Wainwright 发布了对 Sana Biotechnology 收益的乐观预估